- Home
- CING vs APVO Comparison
CING vs APVO Comparison
Compare CING & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- APVO
- Stock Information
- Founded
- CING 2012
- APVO 2016
- Country
- CING United States
- APVO United States
- Employees
- CING N/A
- APVO N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- CING Health Care
- APVO Health Care
- Exchange
- CING Nasdaq
- APVO Nasdaq
- Market Cap
- CING 21.6M
- APVO 21.7M
- IPO Year
- CING 2021
- APVO N/A
- Fundamental
- Price
- CING $3.35
- APVO $1.35
- Analyst Decision
- CING Strong Buy
- APVO
- Analyst Count
- CING 4
- APVO 0
- Target Price
- CING $33.00
- APVO N/A
- AVG Volume (30 Days)
- CING 203.7K
- APVO 815.9K
- Earning Date
- CING 11-13-2025
- APVO 11-06-2025
- Dividend Yield
- CING N/A
- APVO N/A
- EPS Growth
- CING N/A
- APVO N/A
- EPS
- CING N/A
- APVO N/A
- Revenue
- CING N/A
- APVO N/A
- Revenue This Year
- CING N/A
- APVO N/A
- Revenue Next Year
- CING N/A
- APVO N/A
- P/E Ratio
- CING N/A
- APVO N/A
- Revenue Growth
- CING N/A
- APVO N/A
- 52 Week Low
- CING $3.21
- APVO $1.32
- 52 Week High
- CING $6.01
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- CING 39.26
- APVO 40.05
- Support Level
- CING $3.22
- APVO $1.39
- Resistance Level
- CING $3.81
- APVO $1.54
- Average True Range (ATR)
- CING 0.23
- APVO 0.09
- MACD
- CING -0.03
- APVO -0.00
- Stochastic Oscillator
- CING 18.44
- APVO 6.52
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.